Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same
CA 2454538 A1 · Owner: Kirin Holdings Kabushiki Kaisha · Inventors: Fujiwara, Yasunari; Miwa, Atsushi; Nishitoba, Tsuyoshi
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A compound having strong antitumor activity. It is a compound represented by the formula (I) or a pharmaceutically acceptable salt or solvate of the compound: (I) wherein X is CH or nitrogen; Z is oxygen or sulfur; L is oxygen or sulfur; M is CR10R11 (R10 and R11 each is hydrogen alkyl, or alkoxy) or , NR12 (R12 is hydrogen or alkyl); R1 R2, R3 each is hydrogen or optionally substituted alkoxy; R4 is hydrogen; R5 to R8 each is hydrogen halogeno, alkoxy, etc.; and R9 is -R14 alkyl optionally substituted by -T-R15 or - NR16R17 (T is oxygen, sulfur, or NH; R14 is an optionally substituted carbon ring or heterocycle; and R15 to R17 each is alkyl or an optionally substituted carbon ring or …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 21, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 21, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 21, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.